BDP1 and breast carcinoma: Based on the results that anti-HER2 therapies increase MAF1 and TFIIIB expression in HER2-breast cancer cell lines (Table 2, Fig 5), we then queried breast cancer patients treated with anti-HER2 therapies using ROC Plotter [64].